Elevance Health (ELV) beat the quarterly estimate by $1.24 a share on Wednesday. It raised its full-year outlook by 25 cents. The stock closed down 8.5%.
That gap is the whole story. Shares finished at $390.33, off $36.46, while the S&P 500 rose 0.36%. Close to $8 billion of market value disappeared.
A $1.24 Beat and a 25-Cent Raise
Adjusted earnings came in at $7.45 a share against a consensus near $6.21, according to reported estimates. Management lifted full-year adjusted guidance to at least $27.00.
Analysts were already modeling about $26.86 for the year. So a $1.24 quarterly windfall moved the full-year bar roughly 14 cents past where the Street already sat.
Read that plainly. The company told investors the upside does not repeat.
Where the Beat Came From
Elevance said it directly in the release: results were supported by favorable benefit expense performance and an approximately $0.80 per share net below-the-line benefit.
Strip that $0.80 out and the quarter earned about $6.65 against a $6.21 bar. Still a beat, but an ordinary one. Roughly two-thirds of the headline number came from items sitting below the operating line.
The operating line is where the trouble is. Revenue grew 0.8% to $49.8 billion, while adjusted operating profit fell to $1.8 billion from $2.5 billion. The adjusted operating margin dropped to 3.6% from 5.0%.
The Health Benefits segment shows it starkly. Revenue there rose 3% to $42.7 billion while operating profit fell to $0.9 billion from $1.6 billion. That segment now earns a 2.1% margin, down from 3.8%.
This is not a claims blowup. The benefit expense ratio of 89.7% actually landed better than the roughly 90.2% analysts had penciled in. It is an earnings quality problem.
The Medicaid Pool Got Sicker
Elevance pointed to expected elevated medical cost trend in its Government businesses, offset partly by better results in Individual ACA plans.
The mechanism matters more than the label. As states rechecked Medicaid eligibility, healthier members left the rolls and a sicker population stayed behind. Insurers keep collecting a set payment per member while the members who remain cost more to cover.
Elevance leaves the Washington D.C. Medicaid market on August 1 and expects to exit more markets over the next 12 to 18 months where it sees no path to sustainable performance. Medical membership fell by 469,000 in the quarter to 44.9 million.
Not everything is shrinking. The Carelon services and pharmacy arm grew revenue 6% to $19.2 billion, though its operating gain rose just 1% and its margin slipped to 4.9% from 5.2%.
The Selloff Sorted by Medicaid Exposure
The tape graded the read-across with precision. Molina (MOH) fell 3.4% and Centene (CNC) fell 3.1%, the two most Medicaid-dependent names in the group. UnitedHealth (UNH) fell 1.6%, Cigna (CI) fell 1.8%, and Humana (HUM) rose 0.2%.
On valuation, Elevance trades near 17 times trailing earnings, against 32 for UnitedHealth and 13 for Cigna. All three run net profit margins between 2.2% and 2.7%, which is the tell: these are vast revenue machines that keep almost nothing.
Here is the part that gets misread. At $390.33 the stock trades near 14.5 times the company's own adjusted guidance of $27.00, which looks cheap against that 17 times trailing figure.
But the trailing multiple is a GAAP number. Against the matching GAAP guidance of at least $20.10, the stock trades near 19 times, above where it trades on the past year. The forward multiple expands because earnings are falling.
What To Watch
UnitedHealth reports Thursday. If the same government cost trend turns up in the largest insurer's numbers, Wednesday was a preview rather than a company-specific stumble.
Chief executive Gail Boudreaux committed to at least 12% adjusted earnings growth in 2027, measured off the 2026 baseline. That baseline just moved lower, which makes the target easier to hit and less worth hitting.
